Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ulrik Lassen

Showing results (21-30 of 159) with videos related to

Pageof 16
Sort By:
Psycho-Oncology|September 30, 2017
Patient information in phase 1 trials: A systematic reviewKatrine Toubro Gad, Ulrik Lassen, Morten Mau-Søerensen, et al.
Expert Opinion on Pharmacotherapy|March 10, 2011
Irinotecan and bevacizumab in recurrent glioblastoma multiformeJan Nyrop Jakobsen, Benedikte Hasselbalch, Marie-Thérése Stockhausen, et al.
Neuro-Oncology Advances|November 3, 2022
Implementing targeted therapies in the treatment of glioblastoma: Previous shortcomings, future promises, and a multimodal strategy recommendationVincent Fougner, Benedikte Hasselbalch, Ulrik Lassen, et al.
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research|January 23, 2013
The optimality of different strategies for supplemental staging of non-small-cell lung cancer: a health economic decision analysisRikke Søgaard, Barbara Malene B Fischer, Jann Mortensen, et al.
BBA Clinical|April 19, 2017
Detection of copy number alterations in cell-free tumor DNA from plasmaOlga Østrup, Lise Barlebo Ahlborn, Ulrik Lassen, et al.
Neuro-Oncology Advances|May 4, 2026
Patient preferences for incidental findings in a genomic trial: Insights from the Copenhagen glioblastoma cohortAnders Overby Sjøstrøm, Maria Camilla Mathiasen, Ulrik Lassen, et al.
Cancer Management and Research|October 10, 2014
The impact of bevacizumab treatment on survival and quality of life in newly diagnosed glioblastoma patientsHans Skovgaard Poulsen, Thomas Urup, Signe Regner Michaelsen, et al.
Acta Oncologica (Stockholm, Sweden)|July 31, 2010
A Phase I-II dose escalation study of fixed-dose rate gemcitabine, oxaliplatin and capecitabine every two weeks in advanced cholangiocarcinomasUlrik Lassen, Lars Henrik Jensen, Morten Sorensen, et al.
Thescientificworldjournal|February 23, 2013
Sorafenib in advanced hepatocellular carcinoma: a nationwide retrospective study of efficacy and tolerabilityAnne Helene Køstner, Morten Sorensen, René Krøjgaard Olesen, et al.
Oncology|November 29, 2021
Estimating Long-Term Survival Outcomes for Tumor-Agnostic Therapies: Larotrectinib Case StudyAndrew Briggs, Noman Paracha, Katherine Rosettie, et al.
Pageof 16

Showing results (21-30 of 159) with videos related to

Sort By:
Pageof 16
Psycho-Oncology|September 30, 2017
Patient information in phase 1 trials: A systematic reviewKatrine Toubro Gad, Ulrik Lassen, Morten Mau-Søerensen, et al.
Expert Opinion on Pharmacotherapy|March 10, 2011
Irinotecan and bevacizumab in recurrent glioblastoma multiformeJan Nyrop Jakobsen, Benedikte Hasselbalch, Marie-Thérése Stockhausen, et al.
Neuro-Oncology Advances|November 3, 2022
Implementing targeted therapies in the treatment of glioblastoma: Previous shortcomings, future promises, and a multimodal strategy recommendationVincent Fougner, Benedikte Hasselbalch, Ulrik Lassen, et al.
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research|January 23, 2013
The optimality of different strategies for supplemental staging of non-small-cell lung cancer: a health economic decision analysisRikke Søgaard, Barbara Malene B Fischer, Jann Mortensen, et al.
BBA Clinical|April 19, 2017
Detection of copy number alterations in cell-free tumor DNA from plasmaOlga Østrup, Lise Barlebo Ahlborn, Ulrik Lassen, et al.
Neuro-Oncology Advances|May 4, 2026
Patient preferences for incidental findings in a genomic trial: Insights from the Copenhagen glioblastoma cohortAnders Overby Sjøstrøm, Maria Camilla Mathiasen, Ulrik Lassen, et al.
Cancer Management and Research|October 10, 2014
The impact of bevacizumab treatment on survival and quality of life in newly diagnosed glioblastoma patientsHans Skovgaard Poulsen, Thomas Urup, Signe Regner Michaelsen, et al.
Acta Oncologica (Stockholm, Sweden)|July 31, 2010
A Phase I-II dose escalation study of fixed-dose rate gemcitabine, oxaliplatin and capecitabine every two weeks in advanced cholangiocarcinomasUlrik Lassen, Lars Henrik Jensen, Morten Sorensen, et al.
Thescientificworldjournal|February 23, 2013
Sorafenib in advanced hepatocellular carcinoma: a nationwide retrospective study of efficacy and tolerabilityAnne Helene Køstner, Morten Sorensen, René Krøjgaard Olesen, et al.
Oncology|November 29, 2021
Estimating Long-Term Survival Outcomes for Tumor-Agnostic Therapies: Larotrectinib Case StudyAndrew Briggs, Noman Paracha, Katherine Rosettie, et al.
Pageof 16